Remote hearing tests could save cancer Patients' hearing

NCT ID NCT06662058

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests whether offering hearing tests close to home or remotely increases how many head and neck cancer patients get their hearing checked during treatment. Many patients on cisplatin chemotherapy or radiation near the ear can lose hearing, but not all complete recommended monitoring. The trial will compare participation rates among 118 adults receiving these treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could show that remote hearing tests help more patients get monitored for hearing loss during cancer treatment, potentially leading to earlier detection and prevention.
What could go wrong
This is an early-stage study focused on participation rates, not on preventing hearing loss itself. Results may not apply to all cancer types or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK HEAD AND NECK CARCINOMA OF UNKNOWN PRIMARY HEAD AND NECK SQUAMOUS CELL CARCINOMA HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA LARYNGEAL SQUAMOUS CELL CARCINOMA METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA METASTATIC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA METASTATIC LARYNGEAL SQUAMOUS CELL CARCINOMA METASTATIC NASOPHARYNGEAL SQUAMOUS CELL CARCINOMA METASTATIC ORAL CAVITY SQUAMOUS CELL CARCINOMA METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA METASTATIC PARANASAL SINUS SQUAMOUS CELL CARCINOMA NASOPHARYNGEAL SQUAMOUS CELL CARCINOMA ORAL CAVITY SQUAMOUS CELL CARCINOMA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA PARANASAL SINUS SQUAMOUS CELL CARCINOMA RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT NASOPHARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT PARANASAL SINUS SQUAMOUS CELL CARCINOMA STAGE IV CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8 STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8 STAGE IV LARYNGEAL CANCER AJCC V8 STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8 STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 STAGE IV SINONASAL CANCER AJCC V8

Contacts and locations

Locations

  • Emory Midtown University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.